Aspirin not associated with decreased prostate cancer-associated mortality
the ONA take:
According to a recent study published in The Journal of Urology, researchers from Jewish General Hospital in Montreal, Quebec, Canada, have found that aspirin use does not decrease the risk of mortality associated with prostate cancer.
For the study, researchers followed a cohort of 11,779 men diagnosed with nonmetastatic prostate cancer between 1998 and 2009. Patients were followed until 2012 in order to assess associations between aspirin use and both prostate and all-cause mortality.
Results showed that a median follow-up of 5.4 years, aspirin use after cancer diagnosis was associated with increased risks of prostate cancer mortality (HR = 1.46; 95% CI: 1.26-1.50).
Researchers also found that the risk of prostate cancer-associated mortality was increased in patients who started using aspirin after they were were diagnosed with cancer (HR = 1.84; 95% CI: 1.59-2.12), whereas those who were using aspirin before diagnosis did not have an increased risk of cancer-associated mortality (HR = 0.97; 95% CI: 0.81-1.16.
The study showed similar risks for all cause-mortality and post- and pre-diagnostic aspirin use.
Aspirin use does not decrease the risk of mortality associated with prostate cancer.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine
- How Physical Changes From Breast Cancer Affect Self-Image: Considerations for Clinicians
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Atypical Teratoid/rhabdoid Tumors: Challenges and Search for Solutions
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|